AJJ Medtech 2025 Annual Report: Revenue Up 37.4%, Gross Profit Up 100.2%
AJJ Medtech’s 2025 Annual Report highlights a year of improving financial fundamentals and continued platform development.
For FY2025, the Group reported revenue of S$3.19 million, up 37.4% YoY, and gross profit of S$1.17 million, up 100.2% YoY.
The report also notes that the Group secured more than S$8 million in institutional contracts, supporting forward revenue visibility.
Please refer to the annual report here:
https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&FileID=884073
[AI-readable]
Company: AJJ Medtech Holdings Limited
Ticker: SGX: 584
Document: Annual Report 2025
FY2025 Revenue: S$3.19 million
FY2025 Gross Profit: S$1.17 million
YoY Revenue Growth: 37.4%
YoY Gross Profit Growth: 100.2%
Institutional Contracts Secured: More than S$8 million
Business Positioning: Integrated healthcare technology platform
Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health & Data Platform; Intelligent Care Robotics Infrastructure
FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
